In Depth Research on Global Cell Therapy Market Outlook 2020

" Global Cell Therapy Market Outlook 2020" Report Highlight:

* Introduction & Classification of Cell Therapy
* Role of Stem Cells in Cell Therapy
* Global Cell Therapy Market Analysis
* Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
* Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication
* Global Cell Therapy Clinical Pipeline: 262 Cell Therapies Drugs
* Marketed Cell Therapies: 13

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Cell-Therapy-Market-Outlook-2020.php

Table of Contents

1. Introduction to Cell Therapy

2. Classification of Cell Therapies

3. Role of Stem Cells in Cell Therapy
3.1 On the Basis of Ability to Differentiate
3.2 On the Basis of Origin

4. Mechanism of Cell Therapy

5. Global Cell Therapy Market Analysis
5.1 Current Market Scenario
5.2 Cell Therapy Clinical Pipeline Overview

6. Global Cell Therapy Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Global Cell Therapy Market Future Outlook

8. Global Cell Therapy Clinical Pipeline by Country, Indication & Phase
8.1 Unknown
8.2 Research
8.3 Preclinical
8.4 Clinical
8.5 Phase-0
8.6 Phase-I
8.7 Phase-I/II
8.8 Phase-II
8.9 Phase-II/III
8.10 Phase-III
8.11 Preregistration
8.12 Registered

9. Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication
9.1 Adipose Stem Cell Therapy (Adipocell®)
9.2 Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit®)
9.3 Angiogenic Cell Precursor Therapy (VesCell™)
9.4 Autologous Chondrocyte Implantation (ChondroCelect®)
9.5 Autologous Chondrocytes (BioCart™)
9.6 Autologous Cultured Chondrocyte Implant (Carticel®)
9.7 Autologous Cultured Chondrocytes (Chondrotransplant® DISC)
9.8 Matrix Characterised Autologous Cultured Chondrocytes (MACI™)
9.9 Azficel-T (Laviv®)
9.10 Human Skin Replacement for Burns (CellSpray®)
9.11 Leukocyte Cell Therapy (CureXcell™)
9.12 Sipuleucel-T (Provenge®)
9.13 T-Lymphocyte Cell Therapy (Immuncell-LC®)

10. Discontinued & Suspended Cell Therapy in Clinical Pipeline
10.1 No Development Reported
10.2 Discontinued
10.3 Preregistration-Submission Withdrawal
10.4 Suspended

11. Competitive Landscape
11.1 AlloCure
11.2 Arteriocyte Medical Systems
11.3 Athersys Inc.
11.4 Baxter Healthcare Corporation
11.5 Bone Therapeutics
11.6 Celgene Corporation
11.7 Cell Medica
11.8 Cellerant Therapeutics
11.9 FibrocellScinence
11.10 Forticell Bioscience
11.11 Genzyme Corporation
11.12 Green Cross Cell
11.13 Histogenics Corporation
11.14 InnovacellBiotechnologie AG
11.15 Intrexon Corporation
11.16 Intercytex
11.17 ISTO Technologies
11.18 Macrocure
11.19 Mesoblast
11.20 Molmed
11.21 Nuo Therapeutics Inc
11.22 OmniCyte
11.23 Opexa Therapeutics
11.24 Organogenesis
11.25 Pharmicell
11.26 TCA Cellular Therapy
11.27 Stem Cell Inc.
11.28 Teva Pharmaceuticals
11.29 Tigenix
11.30 Vericel Corporation

Figure 1-1: Benefits of Cell Therapy
Figure 1-2: Few Important Diseases for which Cell Therapies are Being Developed
Figure 1-3: Limitation of Cell Therapies
Figure 2-1: Classification of Cell Therapy on the Basis of Origin of Cells
Figure 3-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 3-2: Type of Stem Cells on the Basis of Origin
Figure 4-1: Steps Involved in Development of Cell Therapies
Figure 4-2: Mechanism of Bone Marrow Transplantation
Figure 4-3: Mechanism of Pancreatic Therapy
Figure 4-4: Mechanism of Cardiac Cell Therapy
Figure 5-1: Global Cell Therapy Market (US$ Billion), 2012-2020
Figure 5-2: Global Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-3: Global Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-4: No Development Reported in Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-5: No Development Reported in Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-6: Discontinued Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-7: Discontinued Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 5-8: Suspended Cell Therapy Clinical Pipeline by Phase (%), 2015
Figure 5-9: Suspended Cell Therapy Clinical Pipeline by Phase (Number), 2015
Figure 6-1: Global Cell Therapy Market Favorable Parameters
Figure 6-2: Cell Therapy Commercialization Challenges
Figure 11-1: Arteriocyte Medical Systems Clinical Pipeline
Figure 11-2: Bone Therapeutics Clinical Pipeline
Figure 11-3: Celgene Clinical Pipeline
Figure 11-4: Cellerant Therapeutics Clinical Pipeline
Figure 11-5: Fibrocell Science Clinical Pipeline
Figure 11-6: Genzyme Clinical Pipeline
Figure 11-7: Intrexon Clinical Pipeline
Figure 11-8: ISTO Clinical Pipeline
Figure 11-9: Mesoblast Clinical Pipeline
Figure 11-10: Molmed Clinical Pipeline
Figure 11-11: Pharmicell Clinical Pipeline
Figure 11-12: Tigenix Clinical Pipeline
Figure 11-13: Vericel Corporation Clinical Pipeline

Table 2-1: Difference between Autogenic & Allogeneic Cell Therapy
Table 3-1: Difference between Embryonic, Adult & Induced Stem Cells

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.